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1Introduction
The accidental discovery of penicillin from fungi 
(Fleming, 1929) widely attracted scientific attention for 
the potential role of fungi as antimicrobial agents and 
lead to the discovery and development of other antibiot-
ics. However, the emergence and subsequent spread of 
antibiotic resistant bacterial strains is of increasing con-
cern as reviewed by Levy and Marshall (2004). Currently, 
this problem presents a significant challenge to medicine 
because of the therapeutic failure of life-saving drugs 
(Alfonso, 2005) and hence, more and better antibiot-
ics are needed as indicated by the “10 × ‘20 Initiative” to 
develop 10 new antibiotics by 2020 by Infectious Diseases 
Society of America (2010).
Most fungi-derived pharmaceuticals have been 
sourced from Ascomyceteous fungi where most (but 
not all) species produce microscopic fruiting bodies; 
for example, those used in pharmaceuticals include 
Penicillium, Aspergillus, and so on, whereas perhaps 
fewer pharmaceuticals, certainly in an industrial con-
text, have been derived from the higher phyla of fungi, 
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the Basidiomycota. The Basidiomycota contains an 
abundance of species that produce large fruiting bod-
ies including typical mushrooms, coral fungi, puffballs, 
bracket fungi, and so on. Some species are frequently used 
as a food source such as the common field mushroom, 
Agaricus bisporus (J. E. Lange) Imbach (Agaricaceae); 
others have been used chiefly in medicine (Boa, 2004; 
Molitoris, 1994), whereas some are known for their noto-
riously toxic properties such as Amanitas.
According to Chang and Buswell (1996), the Romans 
perceived mushrooms as “Food of the Gods,” the Chinese 
treasured them as a health food, whereas Lentinula 
edodes (Berk.) Pegler (Marasmiaceae), the shiitake 
mushroom, was highly prized by Japanese emperors as 
an aphrodisiac and was cultivated at secret and heavily 
guarded locations. In accordance with their traditional 
uses, macrofungi have been extensively investigated for 
their therapeutic significance resulting in the discovery 
of an antibiotic pleuromutilin from Pleurotus mutilis (Fr.) 
Sacc. and Pleurotus passeckerianus Pilat (Pleurotaceae) 
(Kavanagh et al., 1951). A number of pleuromutilin 
derivatives have since been developed for veterinary use 
in the treatment of Mycoplasma infections (Drews et al., 
1975; Werner et al., 1978; Hannan et al., 1997; Hunt, 2000; 
Jones et al., 2002; Xu et al., 2009). Furthermore, retapa-
mulin (Altabax) has emerged as an antibiotic for human 
use for the topical treatment of Gram+ve bacterial skin 
infections including methicillin-resistant Staphylococcus 
aureus (Jones et al., 2006; Novak & Shlaes, 2010).
The therapeutic potential of mushrooms has been 
extensively reviewed by Wasser and Weis (1999) and 
Lindequist et al. (2005). Extracts of various fungal fruit-
ing bodies such as Pleurotus ostreatus (Jacq.) P. Kumm. 
(Iwalokun et al., 2007), Pholiota adiposa (Fr.) P. Kumm. 
(Strophariaceae) (Dulger, 2004), Coprinus digitalis 
(Batsch) Fr. (Agaricaceae) (Efremenkova et al., 2003), 
Podaxis pistillaris (L.) Fr. (Agaricaceae) (Al-Fatimi et al., 
2006), Lycoperdon pusillum Batsch [now Bovista pusilla 
(Batsch) Pers.], and Lycoperdon giganteum Batsch [now 
Calvatia gigantea (Batsch) Lloyd] (Lycoperdaceae) 
(Jonathan & Fasidi, 2003) have shown activity against a 
range of different Gram+ve and Gram−ve bacteria and 
also fungi. Stamets (2006) mentioned that macrofungi 
produce numerous novel pharmaceuticals. However, 
only a small proportion (10%) of the total estimated 
number of macrofungi species on Earth (140,000) has 
been described (Hawksworth, 2001). It means that 
there is an enormous inherent scope for the nutritional 
and medicinal value among macrofungi that still needs 
to be discovered. The same is true for the Australian 
macrofungi. Among 10,000 estimated Australian 
macrofungi, <4000 have been described, thus leav-
ing behind a large proportion of macrofungi yet to be 
named indicating the scarce taxonomical information 
available (May, 2003).
Macrofungi have been used as food and medicine 
by indigenous Australians (Kalotas, 1996) but only lim-
ited research has been carried out for the evaluation 
of their antimicrobial potential (Ovenden et al., 2005; 
Beattie et al., 2010). Therefore, considering the previous 
reports on the antimicrobial potential of macrofungi and 
in view of the continuous need for the development of 
new antimicrobials, the present study aimed to evaluate 
a sample of Australian macrofungi for their antibacte-
rial activity against sensitive strains of Staphylococcus 
aureus (Gram+ve) and Escherichia coli (Gram−ve). The 
agar well diffusion and disc diffusion methods are com-
monly used for antimicrobial activity testing but these 
methods have some limitations. For example, some 
compounds may be more diffusible and can produce a 
greater zone of inhibition despite their lower activity in 
comparison with less diffusible compounds that might 
be more active but may produce smaller zone of inhibi-
tion (Janes et al., 2007; Lund et al., 2009). Therefore, in 
the present study, a high-throughput 96-well microplate 
bioassay procedure was used.
Materials and methods
Sample collection
Macrofungi fruiting bodies (47 different species) were 
collected from a range of natural environments across 
Queensland, Australia during May 2008 to October 2009 
(Table 1). The fruiting bodies were identified based on 
sporocarp morphology and macroscopic characters. The 
collections were freeze-dried and stored at −80°C until 
extraction.
Preparation of macrofungi extracts
Freeze-dried macrofungi (500 mg) were macerated in 
25 mL distilled water and then extracted for 1 h in an ultra-
sonic water bath. Following centrifugation (15,000 rpm 
for 15 min), the supernatant was removed. The residue 
was re-extracted with 25 mL water in the sonicating 
water bath for 30 min, centrifuged, and the supernatant 
was pooled with that from the first extraction, collec-
tively forming 50 mL of water extract, which was filtered 
through 0.45-µm membrane filter and freeze-dried. The 
remaining insoluble material was extracted sequentially 
with 100% ethanol and n-hexane, respectively, following 
the same procedure as described for the water extracts. 
The ethanol extracts were evaporated to dryness under 
reduced pressure in a rotary evaporator at 40°C, whereas 
the hexane extracts were evaporated overnight in a fume 
hood.
Preparation of mushroom extracts concentrations
The water extracts were each dissolved in 2 mL of distilled 
water. The ethanol and hexane extracts were first dis-
solved in 400 µL absolute alcohol, sonicated for 10 min, 
and made up to 2 mL with distilled water. This stock solu-
tion was diluted with tryptone soya yeast extract broth 
(TSYEB) to make a concentration of 50% that was serially 
diluted three times with TSYEB to obtain the respective 
concentrations of 25, 12.5 and 6.25% for all the extracts 
tested in the antibacterial assay.
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Test organisms and culture conditions
The sensitive strains of clinically important S. aureus 
strain 6571 [National Collection of Type Cultures (NCTC), 
Health Protection Agency Centre for Infection, London, 
UK] and E. coli strain 9001 (NCTC) were used for the 
screening tests. The organisms were grown in TSYEB 
(CM0129 with the addition of 6 g/L Yeast LP0021, Oxoid, 
Basingstoke, UK) for 24 h. The overnight growth of the 
culture was quantified to an absorbance reading of 0.5 at 
540 nm using a spectrophotometer (Unicam, HeliosAlpha, 
UK) by diluting with TSYEB, to obtain a standard inocu-
lum with 105 CFU/mL for use in the assay.
Table 1. List of macrofungi collected between May 2008 and October 2009 across Queensland, Australia for evaluation of their 
antibacterial activity.
Sample name Location Latitude, longitude
Agaricus aff. xanthodermus Collingwood Park, Brisbane 27°36'47″S, 152°51'47″E
Agaricus sp. 1 Goodna, Brisbane 27°36'04″S, 152°53'57″E
Agaricus sp. 2 University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Agaricus sp. 3 University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Agaricus sp. 4 Redland Bay, Brisbane 27°36'45″S, 153°18'11″E
Agaricus sp. 5 University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Amanita ochrophylla Fraser Island, Central Coast, Qld 19°42'21″S, 145°46'26″E
Amanita flavella Goodna, Brisbane 27°36'34″S, 152°53'57″E
Amanita sp. 1 Goodna, Brisbane 27°36'34″S, 152°53'57″E
Armillaria mellea Brisbane Botanical Garden, Mt. Coot-tha 27°28'37″S, 152°58'40″E
Auricularia auricula-judae University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Boletus sp. subsect. luridi Springbrook NP, South Eastern Qld 28°12'52″S, 153°16'08″E
Cantharellus sp. Cairns, Qld 17°13'06″S, 145°25'54″E
Calvatia sp. Goodna, Brisbane 27°36'34″S, 152°53'57″E
Chlorophyllum molybdites University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Colus sp. University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Coprinus comatus University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Cortinarius sp. Goodna, Brisbane 27°36'34″S, 152°53'57″E
Craterellus sp. Main range NP, Brisbane 27°54'31″S, 152°19'16″E
Cyathus striatus University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Fomitopsis lilacinogilva Fraser Island, Central Coast, Qld 19°42'21″S, 145°46'26″E
Ganoderma sp. 1 University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Ganoderma sp. 2 University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Gymnopus luxurians University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Hexagonia sp. 1 University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Hexagonia sp. 2 Lamington NP, South Eastern Qld 28°15'28″S, 153°08'39″E
Hohenbuehelia sp. Fraser Island, Central Coast, Qld 19°42'21″S, 145°46'26″E
Lentinus sp. 1 University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Lentinus sp. 2 University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Lentinus sp. 3 University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Microporus xanthopus Lamington NP, South Eastern Qld 28°15'28″S, 153°08'39″E
Omphalotus sp. Main range NP, South Eastern Qld 27°54'31″S, 152°19'16″E
Phallus multicolor University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Phallus rubicundus University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Psathyrella sp. University campus, St. Lucia, Brisbane 27°29'52″S, 153°00'46″E
Ramaria sp. 1 Springbrook, South Eastern Qld 28°12'52″S, 153°16'08″E
Ramaria sp. 2 Davis creek national park, Cairns 17°13'06″S, 145°25'54″E
Ramaria zippellii Fraser Island, Central Coast, Qld 19°42'21″S, 145°46'26″E
Russula sp. Mt. Tamborine, South Eastern Qld 27°55'36″S, 153°11'03″E
Russula erumpens Collingwood Park, Brisbane 27°36'47″S, 152°51'47″E
Schizophyllum commune University rainforest, St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Scleroderma sp. Cairns, Qld 17°13'06″S, 145°25'54″E
Scytinopogon angulispora Lamington NP, South Eastern Qld 28°15'28″S, 153°08'39″E
Strobilomyces sp. Cairns, Qld 17°13'06″S, 145°25'54″E
Tylopilus sp. 1 St. Lucia, Brisbane 27°29'37″S, 153°00'21″E
Tylopilus sp. 2 Hardings paddock, South Eastern Qld 27°43'00″S, 152°44'45″E
Tricholoma eucalypticum Goodna, Brisbane 27°36'34″S, 152°53'57″E
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Antibacterial activity assay
A high-throughput 96-well microplate bioassay  procedure 
was used according to the method of Sultanbawa et al. 
(2009), with some modifications. Within each ster-
ile 96-well plate, the first two rows contained 200 µL 
media only (serving as a sterility check). Test samples 
were loaded in the next rows with respective concen-
trations of 50, 25, 12.5 and 6.25%, all comprising 50 µL 
culture  + 150 µL extract. The last row contained 50 µL 
bacterial culture and 150 µL media serving as negative 
control. The experiment was replicated three times in 
separate plates and the same procedure was followed 
for all three extracts. The standard antibiotics, penicil-
lin  G, and oxytetracycline hydrochloride (Sigma-Aldrich, 
St. Louis, MO) were used as the positive controls against 
S. aureus and E. coli.
After loading the samples, the plates were read at 
640 nm (Tecan, Sunrise, Austria) to determine the absor-
bance (t
0
). Then the plates were incubated at 37°C for 
22 h, after which the solutions in the plates were mixed 
using a pipette before measuring the absorbance again 
(t
22
). The percent inhibition was calculated using the 
 formula (Sultanbawa et al., 2009):
% inhibition {1 ( ) ( )} 10022 0 22 0= − − / − ×t t C C
 where C
0
 is the absorbance value of the corresponding 
negative control well at t
0
 and C
22
 is the absorbance value 
of the corresponding negative control well at t
22
.
Results
Overall 141 extracts were prepared, comprising of 
three replicate samples from each of 47 mushroom 
species extracted using three solvents (water, ethanol, 
and hexane). The fruiting bodies used represented 
fungi from 21 families within nine orders from the 
three subclasses (Agaricomycetidae, Phallomycetidae, 
and Agaricomycetes incertae sedis) of the class 
Agaricomycetes. Due to meager taxonomical informa-
tion available for Australian macrofungi, many of those 
collected could be identified to genus level only. Extracts 
were evaluated at four different dilutions (50%, 25%, 
12.5%, and 6.25%) against two contrasting microorgan-
isms, Gram+ve S. aureus and Gram−ve E. coli.
The water and ethanol extracts showed differential activ-
ity against the bacteria (Table 2). Ten macrofungi, namely 
Agaricus sp. 1, Amanita sp., Amanita ochrophylla (Cooke 
& Massee) Cleland; Amanitaceae, Boletus sp. subsect. 
luridi (Boletaceae), Cantharellus sp. (Cantharellaceae), 
Fomitopsis lilacinogilva (Berk.) J. E. Wright & J. R. 
Deschamps; Fomitopsidaceae, Hohenbuehelia sp., 
Lentinus sp. 3, Ramaria sp. 1, and Strobilomyces sp. 
showed excellent inhibition against both bacteria tested in 
the present study with water and/or ethanol extracts. For 
example, the ethanol extract of F. lilacinogilva completely 
inhibited S. aureus and showed good activity against E. 
coli at all the test concentrations (Table 2). On the other 
hand, 11 water extracts, 17 ethanol extracts, and 21 hexane 
extracts possessed either no or weak  antibacterial activity 
against both pathogens. Only a small number of hexane 
extracts exhibited any activity at all; these were Tylopilus 
sp. 2, Cantharellus sp., Psathyrella sp., Cyathus striatus 
(Huds.) Pers. (Nidulariaceae), and Chlorophyllum molyb-
dites (G. Mey.) Massee (Agaricaceae), which were effec-
tive against E. coli only at higher concentrations (data not 
shown).
Discussion
Ethanol has previously been noted as the solvent respon-
sible for extracting components with maximum antimi-
crobial activity (Jonathan & Fasidi, 2003; Dulger et al., 
2004). In the present study, ethanol was similar to water 
in terms of producing extracts with antimicrobial activity. 
This might be due to the sequential extraction procedure 
adopted here, which would have allowed components 
that are soluble in both ethanol and water to have been 
extracted in water, whereas for other studies the same 
active components could be contained within two differ-
ent solvents.
Gram−ve bacteria are generally more resistant to anti-
biotics than Gram+ve, due to the structural complexity of 
their cell wall being less permeable, so consequently anti-
microbials are often less effective against Gram−ve bac-
teria (Costerton & Cheng, 1975; Walsh, 2003). Likewise, 
Gram−ve bacteria have been reported to be less sensitive 
to extracts from macrofungi (Yamac & Bilgili, 2006; Barros 
et al., 2007; Karaman et al., 2009). Similarly, in the present 
study, the extracts were generally less effective toward the 
Gram−ve bacteria (E. coli) as compared with Gram+ve 
bacteria (S. aureus). However, this relationship does not 
hold for every macrofungi. For example, Gbolagade et al. 
(2007) and Tambekar et al. (2006) concluded a better 
inhibitory activity against Gram−ve than Gram+ve bacte-
ria from extracts of A. bisporus, Pleurotus sajor-caju [now 
Lentinus sajor-caju (Fr.) Fr.], Pleurotus florida (Mont.) 
Singer, and Polyporus giganteus [now Meripilus gigan-
teus] (Pers.) P. Karst. In the same way, the ethanol extracts 
of three macrofungi in the present study, Amanita sp. 1, 
Amanita flavella E. J. Gilbert & Cleland (Amanitaceae), 
and Boletus sp. subsect. luridi, showed better activity 
against Gram−ve E. coli rather than Gram+ve S. aureus. 
The better activity of these macrofungi against Gram−ve 
bacteria suggests promising antibacterial potential.
Antibacterial activity was observed amongst represen-
tatives across all the subclasses and nine orders assessed 
in this study (Table 2). Previous screening of macrofungi 
in the order Agaricales (subclass Agaricomycetidae) 
indicated a higher percentage of active isolates (Suay 
et al., 2000). In the present study, certain macrofungi 
from the Agaricales namely, Hohenbuehelia, Amanita, 
and Agaricus revealed strong antibacterial activity. Both 
the water and ethanol extracts of Hohenbuehelia sp. 
exhibited strong inhibition of S. aureus at all four test 
concentrations, whereas E. coli inhibition decreased 
in a dose-dependent manner with the ethanol extract 
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Table 2. Growth inhibition (%) of S. aureus and E. coli with water and ethanol extracts of various macrofungi belonging to the class 
Agaricomycetes.
Sample Conc. (%) 
Water extract Ethanol extract
S. aureus E. coli S. aureus E. coli
Subclass: Agaricomycetidae
Order: Agaricales
Agaricus aff. xanthodermus 50 +++ +++ +++ −
 25 +++ +++ + −
 12.5 +++ − + +
 6.25 ++++ − + +
Agaricus sp. 1 50 ++++ ++++ ++++ −
 25 ++++ ++++ − +
 12.5 ++++ ++++ − +
 6.25 ++++ − − +
Agaricus sp. 2 50 ++ +++ − −
 25 + ++ − −
 12.5 − + − +
 6.25 − + − +
Agaricus sp. 3 50 − + ++++ −
 25 − − +++ ++
 12.5 − − − ++
 6.25 + − − +
Agaricus sp. 4 50 n. d. n. d. ++++ ++++
 25 + + +++ ++++
 12.5 − − + ++
 6.25 − − + +
Amanita sp. 50 ++++ ++++ ++++ ++++
 25 ++++ ++++ ++++ ++++
 12.5 ++ ++++ +++ ++++
 6.25 − ++ + ++++
Amanita flavella 50 − − ++++ ++++
 25 − − +++ ++++
 12.5 − − + ++
 6.25 − − − ++
Amanita ochrophylla 50 ++++ +++ +++ ++++
 25 ++++ +++ + +
 12.5 ++++ + − +
Armillaria mellea 50 ++++ ++++ − −
 25 n. d. n. d. − −
 12.5 ++++ ++++ − −
 6.25 + − − −
Calvatia sp. 50 + − ++++ ++++
 25 − − ++++ ++++
 12.5 − − +++ ++
 6.25 − − + +
Chlorophyllum molybdites 50 ++++ ++++ − ++++
 25 ++ + − ++
 12.5 ++ + − +
 6.25 ++ − − +
Cortinarius sp. 50 ++ − +++ −
 25 ++ − +++ ++
 12.5 ++ − + ++
 6.25 + − − +
Coprinus comatus 50 ++ +++ +++ +++
 25 ++ ++ + +++
 12.5 + ++ − +
 6.25 − + − +
Table 2. continued on next page
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Sample
 
Conc. (%)
Water extract Ethanol extract
S. aureus E. coli S. aureus E. coli
Hohenbuehelia sp. 50 ++++ ++++ ++++ ++++
 25 ++++ ++++ ++++ +++
 12.5 ++++ ++++ ++++ ++
 6.25 ++++ ++++ ++++ +
Psathyrella sp. 50 +++ ++ ++++ ++++
 25 +++ + ++++ ++++
 12.5 ++ − ++++ ++++
 6.25 + − +++ +++
Order: Boletales
Boletus subsect. luridi 50 ++++ ++++ ++++ ++++
 25 + + ++++ ++++
 12.5 − − +++ ++++
 6.25 − + + +++
Strobilomyces sp. 50 ++++ ++++ − −
 25 ++++ ++++ − −
 12.5 +++ ++++ − −
 6.25 + + − −
Tylopilus sp. 1 50 ++++ ++++ ++++ −
 25 ++++ ++ ++ +
 12.5 ++++ + + ++
 6.25 ++++ − + ++
Tylopilus sp. 2 50 ++ − ++++ ++++
 25 ++ − ++++ ++++
 12.5 + + + +++
 6.25 ++ + − ++
Subclass: Phallomycetidae
Order: Phallales
Phallus multicolor 50 +++ + ++++ ++++
 25 +++ + + ++++
 12.5 +++ − − +++
 6.25 + − − ++
Order: Gomphales
Ramaria sp. 1 50 ++++ +++ ++++ ++++
 25 ++++ ++ ++++ ++++
 12.5 ++++ − ++ +++
 6.25 ++++ − +++ +++
Ramaria sp. 2 50 +++ + ++++ ++++
 25 ++ − +++ ++++
 12.5 + − − +
 6.25 + − − −
Ramaria zippellii 50 ++ +++ ++++ ++++
 25 +++ +++ ++ ++++
 12.5 ++ ++ − ++
 6.25 + + − +
Subclass: Agaricomycetes incertae sedis
Order: Polyporales
Ganoderma sp. 1 50 +++ − +++ ++++
 25 − − − +++
 12.5 − − − ++
 6.25 − − − +
Ganoderma sp. 2 50 ++++ − ++++ +
 25 ++ − ++++ ++
 12.5 − − − +
 6.25 − − − +
Table 2. Continued.
Table 2. continued on next page
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from this fungus. Indeed, activity against S. aureus has 
previously been noted for methanol extracts of the fer-
mentation broths of a different species (not yet reported 
in Australia), Hohenbuehelia mastrucata (Fr.) Singer; 
Pleurotaceae collected in Spain (Suay et al., 2000). The 
water extracts of the three Amanita spp. in the present 
study were variable in activity: A. ochrophylla was more 
inhibitory against S. aureus than E. coli, whereas Amanita 
sp. 1 was more effective against E. coli, but A. flavella was 
ineffective against both bacterial species. The ethanol 
extracts from all three Amanita spp. caused greater inhi-
bition of E. coli than S. aureus. In contrast, the methanol 
extract of another Amanita species, Amanita virosa 
(Fr.) Bertill. was ineffective against these same bacterial 
species (Janes et al., 2007). Previous studies have indi-
cated that Agaricus may be a lucrative genus to investi-
gate with regards to antibiotic activity; water extract of 
A. bisporus show activity against Gram−ve bacteria and 
the ethanol extract of Agaricus brasiliensis Wasser, M. 
Didukh, Amazonas & Stamets has been shown to be 
effective against Gram+ve bacteria (Tambekar et al., 
2006; Lund, 2009). The water extract of Agaricus sp. 1 in 
this study exhibited good activity against both Gram+ve 
and Gram−ve bacteria but the water and ethanol extracts 
of the other four Agaricus spp. showed either weak or 
zero activity against the test pathogens. These examples 
from the Agaricales highlight the large variation in activ-
ity between species within each genus but point to the 
potential for using taxonomic relationships as a lead in 
the hunt for antimicrobial activity.
The genus Ramaria (subclass Phallomycetidae) has 
previously indicated potential antimicrobial activity, 
with the methanol extract of Ramaria largentii Marr & D. 
E. Stuntz from Slovenia and ethanol extract of Ramaria 
flava (Schaeff.) Quél. (Gomphaceae) from Turkey show-
ing weak activity against S. aureus while being ineffective 
against E. coli (Gezer et al., 2006; Janes et al., 2007). In the 
present study, the ethanol extracts of all three Australian 
Ramaria sp. tested inhibited the growth of E. coli and 
the water extract of Ramaria sp. 1 revealed strong activ-
ity against S. aureus. Some interesting activity was also 
recorded for macrofungi within subclass Agaricomycetes 
incertae sedis. Complete inhibition of S. aureus was 
achieved with the ethanol extract of Cantharellus sp., 
which also showed strong inhibition of E. coli at higher 
concentrations. While Dulger et al. (2004) concluded 
that the ethanol extract of Cantharellus cibarius was 
more effective against E. coli than S. aureus, our results 
 
Sample
 
Conc. (%)
Water extract Ethanol extract
S. aureus E. coli S. aureus E. coli
Lentinus sp. 3 50 ++++ ++ ++++ ++++
 25 ++++ + ++++ +++
 12.5 ++++ − +++ +++
 6.25 +++ − + ++
Fomitopsis lilacinogilva 50 ++++ − ++++ ++++
 25 ++++ − ++++ ++++
 12.5 ++ − ++++ +++
 6.25 + − ++++ ++
Order: Auriculariales
Auricularia auricula-judae 50 − + ++ −
 25 − − ++ +
 12.5 − − + ++
 6.25 − − + ++
Order: Cantharellales
Craterellus sp. 50 ++++ + − −
 25 +++ − − −
 12.5 +++ − − +
 6.25 ++ − − +
Cantharellus sp. 50 ++++ + ++++ ++++
 25 ++++ − ++++ ++++
 12.5 + − ++++ ++++
 6.25 + − ++++ +++
Order: Russulales
Russula erumpens 50 ++++ − − −
 25 ++ − − −
 12.5 ++ − − +
 6.25 − − + ++
++++ 75–100% inhibition; +++ 50–75% inhibition; ++ 25–50% inhibition; + <25% inhibition; − no activity; n. d. no data; macrofungi 
exhibiting no activity are not shown.
Table 2. Continued.
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are in accordance with Santoyo et al. (2009) and Barros 
et al. (2008). Based on previous tests, Russula may not be 
expected to provide antibacterial compounds, as Keller 
et al. (2002) found that the methanol extracts from five 
different species of European Russula did not possess any 
activity against either Gram+ve nor Gram−ve bacteria. 
Indeed, in our tests extracts of Russula erumpens Cleland 
& Cheel showed only weak activity. Using taxonomic 
relationships as a guide toward bioactivity is only useful 
where records exist. The ethanol extract of F. lilacinogilva 
exhibited complete inhibition of S. aureus and moder-
ate inhibition of E. coli even at the lowest concentra-
tion. Likewise, Popova et al. (2009) and Liu et al. (2010) 
reported that the chloroform extract of Fomitopsis rosea 
(Alb. et Schw. Fr.) Karst and triterpene isolated from 
dichloromethane extract of Fomitopsis pinicola (Swartz 
ex Fr.) Karst inhibited S. aureus and Bacillus cereus. The 
antimicrobial potential of different species in this genus 
suggests that it may be worthwhile further investigating 
closely related species.
In conclusion, this is the first report on the screen-
ing evaluation of different Australian macrofungi spe-
cies. From the results of this study, a small number of 
Australian macrofungi have been identified with promis-
ing antibacterial activity against S. aureus and E. coli that 
can serve as potential candidates for much needed new 
antibiotics. Further work is needed toward the evaluation 
of their antimicrobial potential against a wider range of 
microorganisms and finally the identification and isola-
tion of the active compounds responsible for this activity 
could provide new starting material for the development 
of novel antibiotics.
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